Clinical trials: Community-Acquired Pneumonia
Community Acquired Pneumonia (CAP)
PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Low interventional, prospective, multicentre, hospital-based study involving adults 60 years of age and older hospitalised with CAP at participating sites.
- Trial name
- NCT04613375
- Testing
- Urine sample collection, Saliva collection
- Where
- 5 sites in Spain
- Volunteers
- 1,821 people
- Sponsor
- Pfizer
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
Community Acquired Pneumonia
Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia
A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
- Trial name
- NCT01081964
- Testing
- Zabofloxacin, Levofloxacin 500mg, Zabofloxacin 400mg
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- IASO Pharma Inc.
Infections, Community Acquired Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Community Acquired Bacterial Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01530763
- Testing
- Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 161 people
- Sponsor
- Forest Laboratories
Community-acquired Pneumonia
Oral Nemonoxacin in Treating Elderly Patients With CAP
This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).
- Trial name
- NCT05133752
- Testing
- Nemonoxacin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-acquired Pneumonia
A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
A Phase 1b/2a, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma gelsolin (rhu-pGSN) Added to Standard of Care in Subjects…
- Trial name
- NCT03466073
- Testing
- Recombinant Human Plasma Gelsolin
- Where
- 8 sites in Australia, Georgia
- Volunteers
- 33 people
- Sponsor
- BioAegis Therapeutics Inc.
Pneumonia, Bacterial
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
- Trial name
- NCT00538694
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
Pneumonia
A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.
- Trial name
- NCT00034736
- Testing
- Levofloxacin
- Volunteers
- 691 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sepsis, Community-acquired Pneumonia
A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
- Conditions
- Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute
- Trial name
- NCT04612413
- Testing
- Allocetra-OTS
- Where
- 31 sites in Belgium, France and 3 more
- Volunteers
- 148 people
- Sponsor
- Enlivex Therapeutics Ltd.
Covid19
Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized subjects with severe COVID-19.
- Trial name
- ESsCOVID (NCT04576728)
- Testing
- Trimodulin
- Where
- 17 sites in Brazil, France and 2 more
- Volunteers
- 166 people
- Sponsor
- Biotest
Community Acquired Pneumonia, Bacterial Pneumonia
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization.
- Conditions
- Community Acquired Pneumonia, Bacterial Pneumonia, Cross Infection
- Trial name
- NCT00079885
- Testing
- tigecycline
- Volunteers
- 430 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Infections, Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Complicated Community-acquired Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01669980
- Testing
- Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
- Where
- 21 sites in United States, Argentina and 2 more
- Volunteers
- 40 people
- Sponsor
- Forest Laboratories
Community Acquired Pneumonia
Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
In order to verify the clinical value and safety of Xiyanping injection in children with CAP, we intend to carry out this multi-center, large-sample, non-intervention clinical research through more rigorous and scientific design.
- Trial name
- NCT04158310
- Volunteers
- 9,207 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Bacterial Pneumonia, Community-Acquired Infections
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT02531438
- Testing
- Omadacycline, Moxifloxacin
- Where
- 140 sites in United States, Belgium and 23 more
- Volunteers
- 774 people
- Sponsor
- Paratek Pharmaceuticals Inc
Respiratory Tract Infections
Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine
To describe the relief of symptoms, tolerability, and compliance of treatment with Klacid® sustained release (SR) at a dose of 1000 mg once daily in patients with acute tracheitis, acute tracheobronchitis, acute bronchitis, or in…
- Trial name
- KLARAINE (NCT01095978)
- Testing
- Clarithromycin (Klacid SR)
- Where
- 126 sites in Ukraine
- Volunteers
- 2,822 people
- Sponsor
- Abbott
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT00914888
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community-acquired Pneumonia
A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of intravenous nemonoxacin compared with intravenous moxifloxacin in adult patients with community-acquired pneumonia (CAP).
- Trial name
- NCT02205112
- Testing
- Nemonoxacin, Levofloxacin
- Where
- 63 sites in China, Taiwan
- Volunteers
- 598 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community-Acquired Pneumonia (CAP)
A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older
The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia…
- Trial name
- NCT06782282
- Where
- United States
- Volunteers
- 22,234,435 people
- Sponsor
- Pfizer